Browsing Tag
Pfizer
128 posts
Pfizer resolves $59.7m kickback allegations linked to Biohaven’s marketing practices
Pharmaceutical giant Pfizer Inc., acting on behalf of its subsidiary Biohaven Pharmaceutical Holding Company Ltd., has agreed to…
Pfizer’s BRAFTOVI regimen doubles response rates for metastatic colorectal cancer
Pfizer Inc. has unveiled compelling findings from the Phase 3 BREAKWATER trial, highlighting the efficacy of its BRAFTOVI…
Zai Lab and Pfizer collaborate to address drug-resistant infections in China
Zai Lab and Pfizer have entered a partnership to commercialize XACDURO (sulbactam-durlobactam) in mainland China, addressing the rising…
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising…
FDA approves Pfizer’s HYMPAVZI for breakthrough hemophilia treatment
In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug…
Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately…
Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has…
Pfizer’s CIFFREO Phase 3 study in DMD fails to meet primary endpoint
Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study…
Pfizer secures FDA approval for Hemophilia B gene therapy BEQVEZ
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration’s…
EC authorizes Pfizer’s PREVENAR 20 vaccine for pediatric Use
In a landmark decision, Pfizer Inc. (NYSE: PFE) has been granted marketing authorization by the European Commission (EC)…